NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Apr. 6, 2020--
In response to continued public health concerns about in-person gatherings given the coronavirus/COVID-19 outbreak, the Board of Directors of Lantheus Holding, Inc. (the “Company”) (NASDAQ:LNTH) has determined to change the format of the company’s 2020 Annual Meeting of Stockholders scheduled for Thursday, April 23, 2020 at 11:00 a.m. (Eastern Time) from in-person to virtual-only.
The meeting will be webcast and can be accessed by stockholders at www.proxydocs.com/LNTH using the unique 12-digit control number on their proxy card or voting instruction form. The company has designed the format of the Annual Meeting to ensure that stockholders are afforded similar rights and opportunities to participate as they would at an in-person meeting, using online tools to ensure stockholder access and participation. For additional information regarding accessing and participating in the virtual meeting, please refer to the company’s supplemental proxy materials filed with the Securities and Exchange Commission on April 6, 2020.
As described in the proxy materials for the Annual Meeting, stockholders are entitled to attend and vote at the Annual Meeting only if they held shares as of the close of business on February 24, 2020, the record date designated by the Board for the meeting. Stockholders can continue to vote their shares until 5:00 p.m. (Eastern Time) on April 22, 2020 at www.proxydocs.com/LNTH, by telephone by calling 866-240-5317, or by mail as described in the proxy statement made available on or about March 12, 2020. Stockholders who register to attend the virtual meeting no later than April 21, 2020 at 5:00 p.m. (Eastern Time) will be able to access the virtual meeting from the voting website using the unique 12-digit control number on their updated notice or proxy card that was be mailed or made available on or about March 12, 2020.
About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus Holdings, Inc. is the parent company of LMI, a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension and TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200406005219/en/
Mark Kinarney
Director, Investor Relations
978-671-8842
ir@lantheus.com
Source: Lantheus Holdings, Inc.
